A mechanistic study of proteasome inhibition-induced iron misregulation in dopamine neuron degeneration

NeuroSignals

Volumn 20, Issue 4, 2012, Pages 223-236

  Li, Xu Ping ^a   Xie, Wen Jie ^b   Zhang, Zhen ^a   Kansara, Sagar ^a   Jankovic, Joseph ^a   Le, Wei Dong ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Diana Helis Henry Medical Research Foundation   (United States)

Author keywords

Dopamine neurodegeneration; Iron misregulation; Reactive oxygen species; Ubiquitin proteasome system

Indexed keywords

CD71 ANTIGEN; FERRITIN; IRON; IRON REGULATORY FACTOR; IRON REGULATORY PROTEIN 2; LACTACYSTIN; PROTEASOME; REACTIVE OXYGEN METABOLITE; UBIQUITIN;

AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; CELL CULTURE; CELL DAMAGE; CELL VIABILITY; CONJUGATION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; IRON RESPONSIVE ELEMENT; NERVE DEGENERATION; NUCLEOTIDE SEQUENCE; PROTEIN AGGREGATION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ACETYLCYSTEINE; ANTIGENS, CD; BLOTTING, WESTERN; CELL LINE; CELL SURVIVAL; CYSTEINE PROTEINASE INHIBITORS; DOPAMINERGIC NEURONS; FERRITINS; GENETIC VECTORS; HUMANS; IMMUNOPRECIPITATION; IRON; IRON METABOLISM DISORDERS; IRON-REGULATORY PROTEINS; LENTIVIRUS; NERVE DEGENERATION; PROTEASOME ENDOPEPTIDASE COMPLEX; REACTIVE OXYGEN SPECIES; RECEPTORS, TRANSFERRIN; RNA, SMALL INTERFERING;

EID: 84870054302     PISSN: 1424862X     EISSN: 14248638     Source Type: Journal    
DOI: 10.1159/000332954     Document Type: Article

References (46)

1. Dawson TM, Dawson VL: Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003; 302: 819-822.
2. Rhodes SL, Ritz B: Genetics of iron regulation and the possible role of iron in Parkinson's disease. Neurobiol Dis 2008; 32: 183-195.
3. Salazar J, Mena N, Hunot S, Prigent A, Alvarez-Fischer D, Arredondo M, Duyckaerts C, Sazdovitch V, Zhao L, Garrick LM, Nuñez MT, Garrick MD, Raisman-Vozari R, Hirsch EC: Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease. Proc Natl Acad Sci USA 2008; 105: 18578-18583.
4. Crichton RR, Dexter DT, Ward RJ: Brain iron metabolism and its perturbation in neurological diseases. J Neural Transm 2010; 118: 301-304.
5. Yacoubian TA, Standaert DG: Targets for neuroprotection in Parkinson's disease. Biochim Biophys Acta 2009; 1792: 676-687.
6. McNaught KS, Olanow CW: Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease. Neurobiol Aging 2006; 27: 530-545.
7. Levy OA, Malagelada C, Greene LA: Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps. Apoptosis 2009; 14: 478-500.
8. Bedford L, Hay D, Devoy A, Paine S, Powe DG, Seth R, Gray T, Topham I, Fone K, Rezvani N, Mee M, Soane T, Layfield R, Sheppard PW, Ebendal T, Usoskin D, Lowe J, Mayer RJ: Depletion of 26S proteasomes in mouse brain neurons causes neurodegeneration and Lewy-like inclusions resembling human pale bodies. J Neurosci 2008; 28: 8189-8198.
9. Cook C, Petrucelli LA: Critical evaluation of the ubiquitin-proteasome system in Parkinson's disease. Biochim Biophys Acta 2009; 1792: 664-675.
10. Kaur D, Lee D, Ragapolan S, Andersen JK: Glutathione depletion in immortalized midbrain-derived dopaminergic neurons results in increases in the labile iron pool: implications for Parkinson's disease. Free Radic Biol Med 2009; 46: 593-598.
11. Guo B, Phillips JD, Yu Y, Leibold EA: Iron regulates the intracellular degradation of iron regulatory protein 2 by the proteasome. J Biol Chem 1995; 270: 21645-21651.
12. Wang J, Fillebeen C, Chen G, Biederbick A, Lill R, Pantopoulos K: Iron-dependent degradation of apo-IRP1 by the ubiquitin-proteasome pathway. Mol Cell Biol 2007; 27: 2423-2430.
13. Roth JA, Singleton S, Feng J, Garrick M, Paradkar PN: Parkin regulates metal transport via proteasomal degradation of the 1B isoforms of divalent metal transporter 1. J Neurochem 2010; 113: 454-464.
14. Benarroch EE: Brain iron homeostasis and neurodegenerative disease. Neurology 2009; 72: 1436-1440.
15. Shamoto-Nagai M, Maruyama W, Yi H, Akao Y, Tribl F, Gerlach M, Osawa T, Riederer P, Naoi M: Neuromelanin induces oxidative stress in mitochondria through release of iron: mechanism behind the inhibition of 26S proteasome. J Neural Transm 2006; 113: 633-644.
16. Cozzi A, Rovelli E, Frizzale G, Campanella A, Amendola M, Arosio P, Levi S: Oxidative stress and cell death in cells expressing L-ferritin variants causing neuroferritinopathy. Neurobiol Dis 2010; 37: 77-85.
17. Zhu W, Li X, Xie W, Luo F, Kaur D, Andersen JK, Jankovic J, Le W: Genetic iron chelation protects against proteasome inhibition-induced dopamine neuron degeneration. Neurobiol Dis 2010; 37: 307-313.
18. Gal S, Zheng H, Fridkin M, Youdim MB: Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30. Neurotox Res 2010; 17: 15-27.
19. Mandel SA, Avramovich-Tirosh Y, Reznichenko L, Zheng H, Weinreb O, Amit T, Youdim MB: Multifunctional activities of green tea catechins in neuroprotection. Modulation of cell survival genes, iron-dependent oxidative stress and PKC signaling pathway. Neurosignals 2005; 14: 46-60.
20. Song N, Wang J, Jiang H, Xie J: Ferroportin1 and hephaestin overexpression attenuate iron-induced oxidative stress in MES23.5 dopaminergic cells. J Cell Biochem 2010; 110: 1063-1072.
21. Crawford GD Jr, Le WD, Smith RG, Xie WJ, Stefani E, Appel SH: A novel N18TG2 x mesencephalon cell hybrid expresses properties that suggest a dopaminergic cell line of substantia nigra origin. J Neurosci 1992; 12: 3392-3398.
22. Xu H, Jiang H, Wang J, Xie J: Rg1 protects iron-induced neurotoxicity through antioxidant and iron regulatory proteins in 6-OHDA-treated MES23.5 cells. J Cell Biochem 2010; 111: 1537-1545.
23. Li X, Du Y, Fan X, Yang D, Luo G, Le W: c-Jun N-terminal kinase mediates lactacystin-induced dopamine neuron degeneration. J Neuropathol Exp Neurol 2008; 67: 933-944.
24. Xie W, Li X, Li C, Zhu W, Jankovic J, Le W: Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease. J Neurochem 2010; 115: 188-199.
25. Macchi P, Hemraj I, Goetze B, Grunewald B, Mallardo M, Kiebler MA: A GFP-based system to uncouple mRNA transport from translation in a single living neuron. Mol Biol Cell 2003; 14: 1570-1582.
26. Snyder AM, Connor JR: Iron, the substantia nigra and related neurological disorders. Biochim Biophys Acta 2009; 1790: 606-614.
27. Lee DW, Rajagopalan S, Siddiq A, Gwiazda R, Yang L, Beal MF, Ratan RR, Andersen JK: Inhibition of prolyl hydroxylase protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity: model for the potential involvement of the hypoxia-inducible factor pathway in Parkinson disease. J Biol Chem 2009; 284: 29065-29076.
28. Wetli HA, Buckett PD, Wessling-Resnick M: Small-molecule screening identifies the selanazal drug ebselen as a potent inhibitor of DMT1-mediated iron uptake. Chem Biol 2006; 13: 965-972.
29. Shang T, Kotamraju S, Kalivendi SV, Hillard CJ, Kalyanaraman B: 1-Methyl-4-phenylpyridinium-induced apoptosis in cerebellar granule neurons is mediated by transferrin receptor iron-dependent depletion of tetrahydrobiopterin and neuronal nitric-oxide synthase-derived superoxide. J Biol Chem 2004; 279: 19099-19112.
30. Farout L, Friguet B: Proteasome function in aging and oxidative stress: implications in protein maintenance failure. Antioxid Redox Signal 2006; 8: 205-216.
31. Stankiewicz JM, Brass SD: Role of iron in neurotoxicity: a cause for concern in the elderly? Curr Opin Clin Nutr Metab Care 2009; 12: 22-29.
32. Oakley AE, Collingwood JF, Dobson J, Love G, Perrott HR, Edwardson JA, Elstner M, Morris CM: Individual dopaminergic neurons show raised iron levels in Parkinson disease. Neurology 2007; 68: 1820-1825.
33. Martin WR, Wieler M, Gee M: Midbrain iron content in early Parkinson dise a se: a potential biomarker of disease status. Neurology 2008; 70: 1411-1417.
34. Berg D: Hyperechogenicity of the substantia nigra: pitfalls in assessment and specificity for Parkinson's disease. J Neural Transm 2010; 118: 453-461.
35. Friedman A, Galazka-Friedman J, Koziorowski D: Iron as a cause of Parkinson disease-a myth or a well established hypothesis? Parkinsonism Relat Disord 2009; 15:S212-S214.
36. Vernon AC, Johansson SM, Modo MM: Noninvasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease. BMC Neurosci 2010; 11: 1.
37. Hasinoff BB: The intracellular iron sensor calcein is catalytically oxidatively degraded by iron(II) in a hydrogen peroxide-dependent reaction. J Inorg Biochem 2003; 95: 157-164.
38. Li J, Powell SR, Wang X: Enhancement of proteasome function by PA28-overexpression protects against oxidative stress. FASEB J 2011; 25: 883-893.
39. Keller JN, Huang FF, Dimayuga ER, Maragos WF: Dopamine induces proteasome inhibition in neural PC12 cell line. Free Radic Biol Med 2000; 29: 1037-1042.
40. Papa L, Rockwell P: Persistent mitochondrial dysfunction and oxidative stress hinder neuronal cell recovery from reversible proteasome inhibition. Apoptosis 2008; 13: 588-599.
41. Hentze MW, Muckenthaler MU, Galy B, Camaschella C: Two to tango: regulation of Mammalian iron metabolism. Cell 2010; 142: 24-38.
42. Kaluz S, Kaluzová M, Stanbridge EJ: Does inhibition of degradation of hypoxia-inducible factor (HIF) alpha always lead to activation of HIF? Lessons learnt from the effect of proteasomal inhibition on HIF activity. J Cell Biochem 2008; 104: 536-544.
43. Recalcati S, Minotti G, Cairo G: Iron regulatory proteins: from molecular mechanisms to drug development. Antioxid Redox Signal 2010; 13: 1593-1616.
44. Arosio P, Ingrassia R, Cavadini P: Ferritins: a family of molecules for iron storage antioxidation and more. Biochim Biophys Acta 2009; 1790: 589-599.
45. Dexter DT, Jenner P, Schapira AH, Marsden CD: Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. Ann Neurol 1992; 32:S94-S100.
46. Zhang YH, Mikhael M, Xu D, Li Y, Shan SL, Ning B, Li W, Nie GJ, Zhao YL, Ponka P: Lysosomal proteolysis is the primary degradation pathway for cytosolic ferritin and cytosolic ferritin degradation is necessary for iron exit. Antioxid Redox Signal 2010; 13: 999-1009.